IDH1 and glioblastoma: This survival benefit was not observed in the IDH‐wildtype (IDH‐wt) GBM subgroup (median OS: 17.5 (95% CI: 12.6–24.2) vs. 21.9 (95% CI: 11.9–NA) months, HR = 1.677 (95% CI: 0.7–4.01), p = 0.242) (Figure 2c).